H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $30.00 price target on Cytokinetics (NASDAQ: CYTK) after meeting with management to discuss the outlook for 2020 and beyond. Accordingly, 2020 is expected to be critical for Cytokinetics as the company’s key assets both in the cardiac and skeletal muscle program are set to define their path to regulatory approval.

Regarding GALACTIC-HF's upcoming second interim analysis, we believe that some investors may be anticipating the potential for termination of the study based on efficacy; however, based on discussions with management, while the signal may be there, the DSMB would likely not stop the study unless futile.

For an analyst ratings summary and ratings history on Cytokinetics click here. For more ratings news on Cytokinetics click here.

Shares of Cytokinetics closed at $12.61 yesterday.

You May Also Be Interested In

• Cytokinetics to Announce First Quarter Results on May 8, 2024
• Weatherford International plc (WFRD) PT Raised to $184 at Piper Sandler
• Acrivon Therapeutics Inc (ACRV) PT Raised to $30 at Piper Sandler